Physician profile
Luis Daniel Ramos
NPI 1447754825
$2,444.89
in general payments reported to CMS, 2019-2025
22 companies · $376 in 2025
The $376 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $647 · 2024: $1,423 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $894.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $502.66 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $165.25 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $160.62 | 2023-2024 | Ozempic, Rybelsus |
| Evoke Pharma, INC. | $109.29 | 2024 | |
| Janssen Pharmaceuticals, INC | $77.12 | 2024 | Spravato |
| Pfizer INC. | $71.66 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.55 | 2024 | |
| Braeburn INC. | $49.37 | 2024 | Brixadi |
| Almatica Pharma LLC | $45.44 | 2023-2024 | Loreev Xr |
| Lilly USA, LLC | $44.31 | 2023-2024 | Mounjaro |
| Indivior INC. | $43.39 | 2023-2024 | Sublocade |
| Organogenesis INC. | $35.70 | 2025 | Apligraf |
| Teva Pharmaceuticals USA, INC. | $31.55 | 2023 | Austedo |
| Orexo US, INC. | $26.30 | 2023 | Zubsolv |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $23.20 | 2024 | Gemtesa |
| Mycovia Pharmaceuticals, INC. | $21.35 | 2023 | Vivjoa |
| Merck Sharp & Dohme LLC | $21.27 | 2023 | Belsomra, Steglatro, Steglujan |
| Medtronic, INC. | $20.76 | 2025 | Inceptiv |
| Takeda Pharmaceuticals U.S.A., INC. | $19.41 | 2024 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.63 | 2023 | Trulance, Xifaxan |
| Ets Wound Care LLC | $13.85 | 2025 | Mirragen Advanced Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.